Unknown

Dataset Information

0

Role of MBD3-SOX2 axis in residual myeloma following pomalidomide.

ABSTRACT:

SUBMITTER: Verma R 

PROVIDER: S-EPMC8371090 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Role of MBD3-SOX2 axis in residual myeloma following pomalidomide.

Verma Rakesh R   Branagan Andrew R AR   Xu Mina L ML   Flavell Richard A RA   Dhodapkar Kavita M KM   Dhodapkar Madhav V MV  

Leukemia 20210218 11

Similar Datasets

Unknown MiR-134-Mbd3 axis regulates the induction of pluripotency.
| S-EPMC4882991 | biostudies-literature
Unknown Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).
| S-EPMC12501207 | biostudies-literature
Unknown Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
| S-EPMC4643003 | biostudies-literature
Unknown The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer.
| S-EPMC6408295 | biostudies-literature
Unknown Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide.
| S-EPMC7055313 | biostudies-literature
Unknown The role of the bone microenvironment in regulating myeloma residual disease and treatment.
| S-EPMC9441696 | biostudies-literature
Unknown Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.
| S-EPMC6068091 | biostudies-literature
Unknown Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma.
| S-EPMC10549987 | biostudies-literature
Unknown Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis.
| S-EPMC12432457 | biostudies-literature
Unknown Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
| S-EPMC7685974 | biostudies-literature